In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
NanoViricides (NYSE American: NNVC) announced that its lead candidate NV-387 showed strong antiviral activity against Measles in cell culture and a humanized lethal mouse model, increasing median survival to 17 days from 7.4 days (a 130% increase).
NV-387 treatment correlated with slower disease progression, reduced lung plaques, and lower lung infiltration by lymphocytes and neutrophils. NV-387 completed Phase I with no reportable adverse events and is available as an oral gummy formulation. The company said Measles-specific development is not cost-effective and intends to seek non-dilutive grants while advancing NV-387 for multiple respiratory viruses.
NanoViricides (NYSE American: NNVC) ha annunciato che il suo candidato principale NV-387 ha mostrato una forte attività antivirale contro il morbillo in colture cellulari e in un modello di topo umanizzato letale, aumentando la sopravvivenza mediana a 17 giorni dai 7,4 giorni (un incremento del 130%).
Il trattamento con NV-387 è stato associato a un decorso della malattia più lento, a una riduzione delle placche polmonari e a una minore infiltrazione di linfociti e neutrofili nei polmoni. NV-387 ha completato la Fase I con nessun evento avverso segnalabile ed è disponibile in una formulazione gomosa orale. L’azienda ha dichiarato che lo sviluppo specifico per il morbillo non è economicamente conveniente e intende cercare sovvenzioni non dilutive mentre avanza NV-387 per multiple malattie virali respiratorie.
NanoViricides (NYSE American: NNVC) anunció que su candidato principal NV-387 mostró una fuerte actividad antiviral contra el sarampión en cultivo celular y en un modelo de ratón humanizado letal, aumentando la supervivencia media a 17 días desde 7,4 días (un incremento del 130%).
El tratamiento con NV-387 se asoció con un progreso de la enfermedad más lento, una reducción de las placas pulmonares y una menor infiltración pulmonar de linfocitos y neutrófilos. NV-387 completó la Fase I sin eventos adversos reportables y está disponible en una formulación gomosa oral. La empresa señaló que el desarrollo específico para el sarampión no es rentable y tiene la intención de buscar subvenciones no dilutivas mientras avanza NV-387 para múltiples virus respiratorios.
NanoViricides (NYSE American: NNVC)는 주력 후보물질 NV-387가 세포 배양 및 인간화된 치명적 마우스 모델에서 홍역에 대해 강한 항바이러스 활성을 보였다고 발표했고, 중간 생존 기간을 17일로 증가시켰으며 7.4일에서 증가했습니다(130% 증가).
NV-387 치료는 질병 진행이 더 느려지고 폐의 플라크가 감소하며 림프구와 호중구의 폐 침윤이 감소하는 것과 상관관계가 있었습니다. NV-387은 1상을 보고 가능한 부작용 없음으로 마쳤으며 경구 구미 제형으로 제공됩니다. 회사는 홍역에 대한 개발은 비용 효율적이지 않다고 밝혔고 NV-387를 다수의 호흡기 바이러스에 대해 진행하는 동안 비희석(non-dilutive) 보조금을 모색할 계획이라고 했습니다.
NanoViricides (NYSE American: NNVC) a annoncé que son candidat principal NV-387 a démontré une forte activité antivirale contre la rougeole en culture cellulaire et dans un modèle murin humanisé létal, augmentant la survie médiane à 17 jours contre 7,4 jours (une augmentation de 130 %).
Le traitement par NV-387 était corrélé à une progression de la maladie plus lente, à une réduction des plaques pulmonaires et à une infiltration pulmonaire plus faible par les lymphocytes et les neutrophiles. NV-387 a terminé la Phase I sans événements indésirables signalables et est disponible sous forme de gommes orales. L’entreprise a déclaré que le développement spécifique pour la rougeole n’est pas rentable et envisage de rechercher des subventions non dilutives tout en faisant progresser NV-387 pour plusieurs virus respiratoires.
NanoViricides (NYSE American: NNVC) gab bekannt, dass sein führender Kandidat NV-387 eine starke antivirale Aktivität gegen Masern in Zellkulturen und in einem humanisierten tödlichen Mäusemodell zeigte, wobei die mediane Überlebenszeit von 7,4 Tagen auf 17 Tage anstieg (eine Steigerung von 130%).
Die NV-387-Behandlung korrelierte mit einem langsameren Krankheitsverlauf, einer Reduktion von Lungenplaque und einer geringeren Infiltration von Lymphozyten und Neutrophilen in die Lunge. NV-387 hat die Phase I ohne berichtspflichtige Nebenwirkungen abgeschlossen und ist in einer oralen Gummi-Formulierung erhältlich. Das Unternehmen sagte, dass die krankheitsspezifische Entwicklung für Masern nicht kosteneffizient sei, und beabsichtigt, nicht-dilutive Zuschüsse zu suchen, während NV-387 für mehrere Atemwegsviren vorangetrieben wird.
NanoViricides (NYSE American: NNVC) أعلنت أن مرشحها الرائد NV-387 أظهر نشاطاً مضاداً لفيروسات قوي ضد الحصبة في زراعة الخلايا وفي نموذج فأر بشري مُهيأ عالي الفتك، مما رفع البقاء الوسيط إلى 17 يوماً من 7.4 أيام (ارتفاع 130%).
ارتبط علاج NV-387 بتباطؤ تطور المرض، وتقليل لُثَميات الرئة، وتقلُّص تسلل الخلايا اللمفاوية والعدلات إلى الرئة. أكمل NV-387 المرحلة I بلا تقارير عن أحداث جانبية قابلة للإبلاغ وبصورة فموية علكمية. قالت الشركة أن التطوير المحدد للحصبة ليس مربحاً وتعتزم السعى للحصول على منح غير مخفّضة التخفيف بينما تتقدم NV-387 لعدة فيروسات تنفّسية.
NanoViricides (NYSE American: NNVC)宣布其领先候选药物 NV-387 在细胞培养和人源化致死小鼠模型中对麻疹展现出强抗病毒活性，将中位生存期从 7.4 天 提升至 17 天（增加了 130%）。
NV-387 的治疗与疾病进程变慢、肺部斑块减少以及肺部淋巴细胞和中性粒细胞浸润下降相关。NV-387 已完成 I 期研究，无可报告的不良事件，并以口服软糖形式提供。公司表示针对麻疹的特定开发并不具有成本效益，计划在推进 NV-387 用于多种呼吸道病毒的同时，寻求非稀释性资助。'
- Survival +130% in humanized mice: 7.4 to 17 days
- Phase I completed with no reportable adverse events
- Significant reduction in lung plaques in treated animals
- Reduced lung lymphocyte and neutrophil infiltration
- Oral gummy formulation available for easier dosing
- Company states Measles-specific development is not cost-effective
- IND timing uncertain due to dependence on external collaborators
- Efficacy shown in humanized, immunodeficient mice, limiting direct translation
Insights
NV-387 shows encouraging in vitro and humanized‑mouse activity and Phase I safety, but human efficacy remains unproven.
NV-387 demonstrated direct antiviral activity in cell culture and extended median survival from 7.4 to 17 days in a lethal humanized‑mouse measles model, with correlated reductions in lung plaques and inflammatory cell infiltration. The program also reports completion of a Phase I safety trial with no reportable adverse events and states the drug is being advanced toward Phase II development.
The business mechanism rests on a broad‑spectrum, HSPG‑mimic nanoviricide that claims virus binding and physical disruption, plus an oral gummy formulation intended to aid dosing when swallowing is difficult. Key dependencies and risks include translation of the observed animal survival benefit and lung protection into human clinical efficacy, regulatory acceptance of a novel mechanism and formulation, and the company’s stated need for non‑dilutive funding to progress development.
Concrete items to watch are confirmation of IND/Phase II start dates and endpoints, any human efficacy signals, and regulatory feedback on the mechanism and formulation; monitor near‑term milestones around IND filing and Phase II initiation as they appear.
SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong activity against the Measles virus in cell culture studies as well as in a humanized animal model. Additionally, NV-387 treatment led to protection of lungs which is very important for keeping severely ill patients alive in late-stage viral infections. Currently, there is no approved drug for treating Measles.
Firstly, NV-387 was found to have direct antiviral effects against Measles virus in standard cell culture-based testing that measured increase in the extent of surviving infected cells upon treatment with the drug (i.e. "CPE" or Cytopathic Effects Assay).
Additionally, in a lethal Measles infection humanized animal model, NV-387 treatment led to a substantial increase in the number of survival days, to 17 days in NV-387-treated animals, from only 7.4 days in untreated animals, an increase of
The increased survival correlated with several improvements in the animal health indicating control of viral infection:
Slow disease progression, and mild to moderate levels of lung damage as observed in microscopic histopathology.
Protection of lungs was also evident from the significant reduction in the level of lung plaques (damage to lung tissue) compared to untreated cases.
Reduction in the level of lung-damaging lymphocytes and neutrophils attracted into the lungs (i.e. infiltration).
These observations indicated that NV-387 treatment led to beneficial effects that protected lungs as well as reduced overall systemic infection.
We have thus found that NV-387 has dual benefits of (i) directly reducing the virus itself, together with (ii) protecting systemic cellular damage, and in particular, protecting lungs from viral damage as well as self-inflicted damage from killer cells.
These benefits make NV-387 an unusual and highly desirable antiviral drug.
NV-387 has completed Phase I clinical trial in healthy subjects with no reportable adverse events, and was found to be safe and well tolerated. In IND-enabling studies, NV-387 was found to be extremely safe and well tolerated in animal models. NV-387 was found to be non-immunogenic, non-allergenic, non-mutagenic, and non-genotoxic.
NV-387 acts by a unique mechanism of action that we call "Re-Infection Inhibition". NV-387 is designed as a mimic of heparan-sulfate proteoglycan (HSPG) structures that are used by over
NV-387 is available as Oral Gummies, which dissolve slowly in the mouth; and do not require swallowing. Swallowing can be difficult for a patient in presence of a rash.
With Measles outbreaks spreading all across the country, the USA is expected to lose the Measles elimination status, and the virus would be considered endemic thereafter as it was before 2000. Vaccination against Measles is effective, but there are limitations to its public health potential. Measles is extremely contagious, and more than
Further, it has become clear in recent years that the Measles virus is drifting from the current vaccine strain (circa 1968) over the last fifty-plus years, and there is some evidence that some variants may have arisen that have greater resistance to the vaccine than in the past.
Thus a drug for combating this emerging infectious disease of Measles is important. As a Company, we note that regulatory development of a drug specific for Measles is not cost-effective, and we will continue to seek non-dilutive grants and contracts support for further development of NV-387 as a treatment for Measles.
NV-387 can be readily developed for Measles through FDA licensure, because it is a multi-purpose, broad-spectrum antiviral. NV-387 is being developed to treat several different viral infections acquired by the respiratory route.
NanoViricides is working on regulatory development of NV-387 as a treatment for viral infections that include RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, as well as the epidemic-threatening virus causing MPox and the bio-terrorism threat virus of Smallpox.
NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.
Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
1Humanized mice were required for the animal model because Measles virus only infects humans, and specifically uses hSLAM as the cognate receptor for cell entry, while using the ubiquitous HSPG for congregation next to cells. The mice had human hSLAM (aka hCD150) gene knocked-in, and also had their interferon responses deleted (hSLAM+k.i., IfnAR-/- transgenic mice on C57BL/6 Background). NV-387 mimics the portions on HSPG that viruses bind to, including the Measles virus, and thereby is designed to attack and engulf the virus particle via lipid-lipid mixing and destroying the virus particle's ability to infect cells.
SOURCE: NanoViricides, Inc.
View the original press release on ACCESS Newswire
FAQ
What Measles results did NanoViricides (NNVC) report on October 22, 2025?
Did NV-387 show safety in human trials for NNVC?
How does NV-387 protect lungs in the Measles model (NNVC)?
Will NanoViricides (NNVC) file an IND for NV-387 and when?
How might NNVC’s NV-387 availability as an oral gummy affect patients?
Does NNVC plan to commercialize NV-387 for Measles only?
